- Benchmark's revenue increased by 25% to GBP44.2m in the year ended 30 September driven by the group's breeding & genetics division.

The loss before tax rose to GBP11.4m (2014: GBP1.4m) as it accelerated investment in scientific R&D and felt the impact of a generic competitor to Salmosan/Byelice in Chile and EBITDA from trading activities fell to £2.4m (2014: £6.6m) as it invested in corporate infrastructure.

Chief executive Malcolm Pye said: "It has been a busy year for the Company. Following the acquisition of Salmobreed and Stofnfiskur last year we have successfully integrated the new Breeding and Genetics division, and are particularly proud of its contributions to the Group's revenues. Our strategy of diversification has proven successful, and that endeavour will be furthered again following the transformational INVE acquisition. Our continued investment into R&D has seen our product pipeline increase from 47 to 61, and we are continuing to develop cutting edge capabilities at our research and manufacturing facilities in Ardtoe and Braintree.

"Benchmark has always been committed to targeted M&A activity, and has recently completed the transformational acquisition of INVE Aquaculture. This newest addition to the Group creates the fifth and final 'cog' in our gearbox, and allows us the increased reach and the platform needed to rapidly scale the Company."

At 8:44am: [LON:BMK] Benchmark Holdings Plc Ord 0.1p share price was -2p at 67p

Story provided by